The Hippo pathway is an evolutionarily conserved regulator of organ size and tumorigenesis that negatively regulates cell growth and survival. Whether the Hippo pathway regulates cell metabolism is unknown. Here, we report that in the nucleus of 
| INTRODUC TI ON
Obesity and type 2 diabetes are characterized by insulin resistance, non-alcoholic fatty liver disease and dyslipidaemia, which leads to an increased risk of cardiovascular disease. 1 Sterol regulatory element binding protein (SREBPs) are key lipogenic transcription factors that are mainly comprised of SREBP-1c and SREBP-2 in liver. 2, 3 SREBP-1c and SREBP-2 regulate lipogenic process and cholesterol homeostasis respectively, by activating genes involved in these processes. 4 When activated by insulin, the precursors of SREBPs migrate from the endoplasmic reticulum (ER) membrane to the Golgi and undergoes sequential proteolytic processing to release the transcriptionally active N-terminal basichelix-loop-helix (bHLH-Zip) domain. The active forms of SREBP-1c and SREBP-2 translocate into the nucleus, bind to sterol regulatory elements (SREs) present in the promoters of their own and target genes, and activate the transcription of SREBP-responsive genes, thereby promoting the lipogenic process in the liver. 5 The pathogenesis of hepatic steatosis, dyslipidaemia, and type 2 diabetes is closely related to the dysregulation of SREBPs. 6 The Hippo pathway was initially defined by genetic studies in Drosophila melanogaster, which is an evolutionarily conserved controller of both cell proliferation and apoptosis. Recent studies show that in transgenic mice, YAP promotes liver enlargement in a versible manner, 16 suggesting that liver size control relies on tight regulation of Hippo pathway activity. Whether YAP affects the hepatocytes metabolism in this process needs further research. In addition, YAP/TAZ activation in tumour cells is promoted by increased levels of mevalonic acid produced by SREBPs transcriptional activity, which is induced by its oncogenic cofactor mutant p53. 17 Furthermore, Lats2, a component of Hippo signalling, has been shown to suppress hepatic cholesterol accumulation by inhibiting SREBPs. As there are some connections between Hippo pathway and SREBPs, it is interesting for us to explore the role of Hippo-YAP signalling in the lipid and cholesterol metabolism in liver.
Here, we show that SREBPs act as downstream effectors of Hippo-YAP signalling to regulate the triglyceride and cholesterol metabolism of hepatocytes. Activation of Hippo signalling by ad-Lats1 or sh-YAP ameliorates insulin resistance, hepatic steatosis and hyperlipidaemia in diabetic mice. 18 Plasma, liver tissue and hepatocellular triglyceride and cholesterol levels were analysed as described. 
| ME THOD

| Animal protocols and diet
| Primary mouse hepatocyte isolation and culture
Sodium pentobarbital (30 mg/kg intraperitoneally) were used to anaesthetize the C57BL/6 mouse. Primary mouse hepatocytes were isolated and cultured as described previously. 20 Cell density was controlled at the same level by cell counting before the experiments.
| Antibodies
Antibodies used for immunoblots were purchased from the indicated companies: p-YAP (Ser127) (NO.13008), YAP (NO.14074), Lats1 (NO.3477), pLats1 (Ser909) (NO.9157), and pLats1 (Thr1079) (NO.8654) were from (Cell Signalling Technology). SREBP-1 (Cat#557036), SREBP-2 (Cat#557037) were from BD Biosciences.
| Liver histological and immunohistochemical analysis
When experimental mice were sacrificed, livers of the mice were rapidly fixed in 10% phosphate-buffered formalin acetate at 4°C overnight and embedded in paraffin wax. Paraffin sections (5 μm)
were cut and mounted on glass slides. After dehydration, the haematoxylin and eosin and immunohistochemistry staining were made as according to the research. 
| Adenovirus constructs
Adenovirus harbouring Lats1 (ad-Lats1) and adenovirus harbouring shRNA for YAP (Ad-sh-YAP) were made according to previous research. 21, 22 Adeno-X Maxi Purification Kit (Clontech) was used to purify the adenoviruses.
| Chip and sequential chip
ChIP and sequential ChIP were conducted according to previous research. 
| Immunoprecipitation
Primary mouse hepatocytes lysates were prepared using lysis buffer 
| Transient transfection and dualluciferase assays
The reporter gene plasmids including human SREBP-1c-luc, SREBP-2-luc (including three canonical SREBP-1c -response elements [SRE] ) and the SRE mutant promoter of SREBP-1c-luc and SREBP-2-luc in the luciferase reporter vector pGL3-Enhancer (Promega) were previously described. 23, 24 The FAS-Luc and HMGCR-Luc reporter plasmid were previously reported. 25, 26 Cells were plated on 12-well plates and transfected with indicated luciferase vectors and Renilla luciferase plasmid pRL-SV40 (Promega) as an internal control, the ratio of luciferase vector and Renilla plasmid was 50:1. The transcriptional activity was determined using a luciferase assay system (Promega). Values were standardized using β-actin. Data were analysed using the ΔΔCT threshold cycle method.
| RNA isolation and quantitative RT-PCR
| Immunoblot analysis
Extracts of liver homogenates or cell lysates were prepared using the extraction reagent kit (Pierce Biotechnology Inc) according to the manufacturer's instructions. Equal amounts of protein (10-20 µg) were subjected to 10%-15% SDS-PAGE, transferred to a PVDF membrane and probed with the indicated antibodies.
| Statistical analysis
All values are expressed as mean ± SEM Statistical analysis between groups was conducted by unpaired Student's t test or one-way analysis of variance (ANOVA) followed by a NewmanKeuls comparison test. Values of P < 0.05 were considered to be significant.
| RE SULTS
| YAP is dephosphorylated and translocates into nucleus of hepatocytes in HFHS-fed mice
The diabetogenic diet composed of high fat and high sucrose (HFHS), previously described to promote obesity and type 2 diabetes in C57BL/6 mice, could induce hepatic steatosis, hyperlipidaemia, insulin resistance and enhanced atherosclerotic plaques in mice.
27,28
In order to explore the phosphorylation status of YAP in diabetic mice, C57BL/6 mice were placed on either a normal chow diet or a HFHS diet for 16 weeks. Immunohistochemistry of the liver showed YAP protein was mainly located in cytoplasm of hepatocytes in mice with normal diet. But in mice fed with HFHS diet, YAP protein accumulated and translocated into nucleus of hepatocytes ( Figure 1A ).
Western blot was also performed and reflected that, in diabetic mice, the YAP protein was increased and dephosphorylated at serine 127 ( Figure 2B ), which promotes YAP nuclear translocation and activation. 7 Furthermore, we cultured the primary hepatocytes of mice and stimulated the cells with mevalonic acid (MVA), which was accumulated in diabetic mice and reported to induced YAP nuclear locali- F I G U R E 1 YAP protein is dephosphorylated and activated in liver of HFHS diet-fed mice. A, Representative immunohistochemical staining for YAP protein in mice with normal diet or HFHS diet. YAP was accumulated in the nucleus of hepatocytes in mice with HFHS diet. Photographs were taken at magnifications of ×400. Nuclear YAP were quantified (mean ± SEM, *P < 0.05, vs Normal Diet, Scale bars, 50 μm). B, Primary hepatocytes from mice (n = 4) were treated with dimethylsulphoxide (DMSO) or with 0.5 mmol/L MVA for 24 h before fixation. Representative images of immunofluorescence for YAP protein were shown. Primary hepatocytes with nuclear YAP were quantified (mean ± SEM, *P < 0.05, vs DMSO, scale bars, 15 μm). C, Western blot analysis of YAP and pYAP (S127) in mice with normal diet or HFHS diet. D, The mRNA levels of YAP in primary hepatocytes from mice (n = 4) were detected by RT-PCR (mean ± SEM, *P < 0.05, vs DMSO). E, Total YAP and pYAP (S127) protein were detected by Western blot
| Phosphorylation of YAP by ad-Lats1 improves systemic insulin resistance and hepatic steatosis in diabetic mice
Lats1, acting directly upstream of the Hippo pathway effector YAP, phosphorylates YAP at Ser127 and induces YAP nuclear exclusion and cytoplasmic retention. 31 To research the role of Hippo pathway in the lipid metabolism, we first phosphoryl- Then, we wanted to explore the role of Hippo pathway in the diabetic mice. C57BL/6 mice were fed with either a normal chow diet, a HFHS diet or a HFHS diet for 16 weeks and administrated with ad-Lats1 or the control adenoviruses. As shown in F I G U R E 2 Lats-1 protects against insulin resistance and hepatic steatosis in HFHS diet-fed mice. A and B, Plasma insulin levels and blood glucose were assessed in mice fed a normal chow diet with ad-con (n = 15), a HFHS diet with ad-con (n = 30) and a HFHS diet with ad-Lats1 (n = 30). C and D, Time course changes of plasma triglyceride and total cholesterol levels in mice following a 16 h fast (n = 8-16). E and F, mRNA levels of FAS and HMGCR and changes of body weight in mice (n = 15-30). G, Representative gross morphology of the mouse livers, Haematoxylin and eosin staining and oil red O staining of liver sections (n = 8-16). Photographs were taken at magnifications of ×200. The degree of lipid infiltration on Haematoxylin and eosin staining was scored, scale bars, 50 μm. Data are shown as mean ± SEM, *P < 0.05, vs normal diet mice with ad-con; # P < 0.05, vs HFHS-fed mice with ad-con Figure 2A ,B, ad-Lats1 caused an obvious reduction in plasma insulin and a mild decrease in plasma glucose in mice fed with HFHS 
| YAP binds to SREBPs and functions as a transcriptional co-activator of SREBPs
Since the terminal effector of Hippo signalling pathway, YAP, always functions as a co-activator of the transcription factor, we performed co-immunoprecipitation assays to confirm that endogenous YAP associates with SREBP-1c and SREBP-2 in mouse liver hepatocytes ( Figure 5A,B) . Furthermore, IP showed the pYAP did not bind to SREBPs, demonstrating that only the dephosphorylated and activated YAP could associate with SREBPs (Supplementary Figure S1H) . Then, we evaluated transcriptional activity of the SREBP1c-luciferase reporter gene (S1C-luc) driven by three canoni-
cal SREBP-1cresponse elements (SREs). YAP stimulated SREBP-1c
transcriptional activity in a dose-dependent manner, and this effect was reduced by overexpressing Lats1 ( Figure 5C ). Similarly, Lats1 could reverse the stimulation effect of YAP on SREBP-2-luc (S2-luc) ( Figure 5C ). Moreover, mut-YAP (S127A), not being dephoryphoslated, could also increase more activity of S1C-luc and S2-luc, compared with the wild-type YAP ( Figure 5D ). As SREBPs could bind to the promoter region of their own via a feed-forward mechanism, chromatin immunoprecipitation (ChIP) was conducted to confirm YAP present at the same region in primary mice hepatocytes. ChIP results showed that YAP was shown at the SREBP-binding motifs in the promoter regions of SREBPs and Lats1 overexpression could inhibit the process ( Figure 5E ). Taken together, these data indicate that YAP binds to SREBP-1c and SREBP-2, and acts as a transcriptional co-activator of these two transcriptional factors.
| The YAP-SREBPs complex mediates SREBP target genes expression in vitro
To 
| Hippo signalling suppresses SREBPs target genes expression
We vs empty vector plus 50 ng YAP, ΔP < 0.05 vs empty vector plus 100 ng YAP, mean ± SEM, n = 3). HepG2 cells were co-transfected with SREBP-2-luc vector and the indicated expression vectors. After 48 h, the luciferase activity was measured, demonstrating that YAP enhanced SREBP-2 transcriptional activity. Overexpression of Lats1 inhibited SREBP-2 activity (*P < 0.05 vs empty vector, # P < 0.05 vs empty vector plus YAP, mean ± SEM, n = 3). D, YAP or mut-YAP was co-transfected with SREBP-1c-luc/SREBP-2-luc vector or mut-SREBP-1c-luc/SREBP-2-luc vector in HepG2 cells. After 48 h, the luciferase activity was measured (*P < 0.05 vs empty vector plus S1C-luc, # P < 0.05 vs YAP plus S1C-luc, mean ± SEM, n = 3). E, ChIP analysis of in vivo YAP binding to the SREBP-1c and SREBP-2 promoters. Primary hepatocytes were transfected with indicated adenovirus for 48 h. Protein-bound chromatin was prepared and immunoprecipitated with IgG and YAP antibodies. Lats1 overexpression attenuated the binding. The relative occupancy on the promoters was compared with the input signal (*P < 0.05 vs ad-con plus IgG, # P < 0.05 vs ad-con plus YAP, mean ± SEM, n = 3)
Recent researches indicate that YAP activity is regulated by the leads to the increased mevalonic acid and promotes YAP activity in tumour cells. 17 These results reveal a tight connection between YAP activity and cell lipid and cholesterol metabolism.
In our researches, we discover that YAP could also be activated by mevalonic acid in primary mice hepatocytes. And in mice fed with or SREBP-2 (C), mean ± SEM, n = 3). D, HepG2 cells were transfected with the FAS-luc vector and the indicated vectors and siRNAs. After 48 h, luciferase activity was measured (*P < 0.05 vs empty vector plus si-con, # P < 0.05 vs 50 ng nSREBP-1c plus si-con, ΔP < 0.05 vs 100 ng nSREBP-1c plus si-con, mean ± SEM, n = 3). E, HepG2 cells were transfected with the HMGCR-luc vector and the indicated vectors and siRNAs. After 48 h, luciferase activity was measured (*P < 0.05 vs empty vector plus si-con, # P < 0.05 vs 50 ng YAP plus si-con, ΔP < 0.05 vs 100 ng YAP plus si-con, mean ± SEM, n = 3). F, Primary hepatocytes transfected with the sh-YAP were exposed to high glucose (HG) plus insulin. After 24 h, mRNA levels of FAS and HMGCR were detected by RT-PCR (*P < 0.05 vs control group, # P < 0.05 vs HG + insulin group, mean ± SEM, n = 3). G, Protein levels of FAS and HMGCR exposed to HG plus insulin were inhibited by sh-YAP treatment in primary hepatocytes.
HFHS diet, YAP is activated and translocated from cytoplasm into nucleus of hepatocytes, which may be attributed to the increased The relative occupancy on the promoters was compared with the input signal (*P < 0.05 vs ad-con plus IgG, # P < 0.05 vs ad-con plus YAP, mean ± SEM, n = 3). C, HepG2 cells were transfected with the FAS-luc vector and the indicated si-RNAs. After 48 h, luciferase activity was measured (*P < 0.05 vs si-con, # P < 0.05 vs si-Lats1, mean ± SEM, n = 3). D, Overexpression of Lats1 reduced FAS and HMGCR mRNA and protein levels. Primary hepatocytes were exposed to high glucose (HG) plus insulin transfected with the ad-Lats1. After 24 h, mRNA levels of FAS and HMGCR were detected by RT-PCR (*P < 0.05 vs control group, # P < 0.05 vs HG + insulin group, mean ± SEM, n = 3). E, Protein levels of FAS and HMGCR exposed to HG plus insulin were inhibited by ad-Lats treatment in primary hepatocytes. F, Knockdown of Lats1 increase lipid accumulation in HepG2 cells exposed to HG plus insulin, as reflected by oil red O staining, whereas knockdown of YAP or SREBP-1c reverse this effect. Photographs were taken at magnifications of ×400, scale bars, 50 μm mice, Hippo signalling is inhibited and YAP is dephosphorylated and translocates into the nucleus of hepatocytes, functioning as a co-activator of SREBP-1c and SREBP-2, which contributes to lipogenesis and cholesterol synthesis. As the relationship of Hippo pathway and many other nutrients metabolism still remains unclear, it would be interesting to explore the role of Hippo-YAP signalling in other cell metabolic processes, such as proteometabolism and glycometabolism. Whether YAP could be a regulator for these processes needs further research.
In a recent research, Lats2 was shown to inhibit SREBPs and suppresses hepatic cholesterol accumulation through a Lats2-p53 axis. 35 Mice harbouring liver-specific Lats2 conditional knockout displayed SREBP activation, leading to spontaneous fatty liver disease. 35 Furthermore, only Lats2, not Lats1, could inhibit SREBPs proliferation. 37, 38 In addition, increasing lines of evidence suggest that the hyperactivation of YAP, due to inactivation of Hippo signalling, promotes cell proliferation and acts as a tumour promoter in many organs. 7 Thus, it is tempting to speculate that YAP-SREBPs complex may regulate tumorigenesis through controlling cell lipogenesis genes.
LXRα regulates fatty acid and triglyceride synthesis, as it induces SREBP-1c activation and expression via an LXR response element in its promoter. 41, 42 mTORC1 is also an critical controller of SREBP-1c
since it can activate SREBP-1c transcription in response to insulin stimulation. 43 Here, we show that YAP functions as a coactivator of SREBPs and YAP knockdown decreases their activities. These multiple transcriptional controllers of SREBPs may control their expression in a coordinated and stimulus-specific manner.
It is known that SREBPs are associated with the SREBP cleavage activating protein (SCAP) and ER retention protein called Insig.
44
To be activated, the SREBP-SCAP complex should dissociate from
Insig, associate with COPII-coated vesicles and then migrate to the Golgi apparatus for proteolytic activation. 45 We here showed that diabetic mice with ad-Lats1 or sh-YAP share some features with SCAP knockout mice or transgenic mice overexpressing Insig-1, decreased nSREBPs. 46, 47 In addition to the transcriptional regulation, it would be of interest to determine whether Hippo signalling regulates SREBPs proteolytic processing in hepatocytes.
In conclusion, our research reveals a novel relationship between the Hippo pathway and SREBPs through YAP, and describes the mechanism of this regulation in the pathogenesis of diabetic mice.
We speculate that the connection between YAP and SREBPs is a point of convergence that allows Hippo pathway to precisely control many biological processes in metabolic disease.
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